News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
251,639 Results
Type
Article (13951)
Company Profile (24)
Press Release (237663)
Multimedia
Podcasts (23)
Webinars (3)
Section
Business (71662)
Career Advice (1123)
Deals (14524)
Drug Delivery (51)
Drug Development (34688)
Employer Resources (47)
FDA (6672)
Job Trends (5830)
News (125887)
Policy (10369)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
Academia (777)
Accelerated approval (18)
Adcomms (7)
Allergies (80)
Alliances (11303)
ALS (96)
Alzheimer's disease (701)
Antibody-drug conjugate (ADC) (197)
Approvals (7015)
Artificial intelligence (289)
Autoimmune disease (90)
Automation (23)
Bankruptcy (111)
Best Places to Work (4937)
BIOSECURE Act (4)
Biosimilars (129)
Biotechnology (23)
Bladder cancer (134)
Brain cancer (36)
Breast cancer (437)
Cancer (3152)
Cardiovascular disease (255)
Career advice (901)
Career pathing (12)
CAR-T (143)
CDC (13)
Cell therapy (395)
Cervical cancer (26)
Clinical research (32281)
Collaboration (954)
Compensation (545)
Complete response letters (18)
COVID-19 (1055)
CRISPR (50)
C-suite (356)
Cystic fibrosis (64)
Data (4300)
Depression (87)
Diabetes (287)
Diagnostics (2511)
Digital health (20)
Diversity (1)
Diversity, equity & inclusion (13)
Drug discovery (141)
Drug pricing (76)
Drug shortages (12)
Duchenne muscular dystrophy (146)
Earnings (53747)
Editorial (22)
Employer branding (10)
Employer resources (44)
Events (36415)
Executive appointments (458)
FDA (8630)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (17)
Funding (878)
Gene editing (113)
Generative AI (20)
Gene therapy (325)
GLP-1 (619)
Government (1605)
Grass and pollen (5)
Guidances (358)
Healthcare (6876)
HIV (45)
Huntington's disease (24)
IgA nephropathy (54)
Immunology and inflammation (141)
Immuno-oncology (42)
Indications (80)
Infectious disease (1234)
Inflammatory bowel disease (89)
Inflation Reduction Act (6)
Influenza (91)
Intellectual property (104)
Interviews (198)
IPO (8533)
IRA (11)
Job creations (1190)
Job search strategy (774)
JPM (34)
Kidney cancer (15)
Labor market (43)
Layoffs (205)
Leadership (14)
Legal (2118)
Liver cancer (53)
Longevity (6)
Lung cancer (462)
Lymphoma (283)
Machine learning (23)
Management (11)
Manufacturing (374)
MASH (98)
Medical device (5084)
Medtech (5114)
Mergers & acquisitions (6660)
Metabolic disorders (775)
mRNA (67)
Multiple sclerosis (101)
NASH (11)
Neurodegenerative disease (188)
Neuropsychiatric disorders (61)
Neuroscience (1423)
NextGen: Class of 2026 (2073)
Non-profit (1548)
Now hiring (34)
Obesity (388)
Opinion (84)
Ovarian cancer (94)
Pain (111)
Pancreatic cancer (128)
Parkinson's disease (171)
Partnered (12)
Patents (202)
Patient recruitment (230)
Peanut (33)
People (9139)
Pharmaceutical (11)
Pharmacy benefit managers (11)
Phase 1 (8709)
Phase 2 (13919)
Phase 3 (12343)
Pipeline (4072)
Policy (71)
Postmarket research (1211)
Preclinical (2976)
Press Release (15)
Prostate cancer (174)
Psychedelics (24)
Radiopharmaceuticals (122)
Rare diseases (489)
Real estate (1351)
Recruiting (20)
Regulatory (9000)
Reports (25)
Research institute (816)
Resumes & cover letters (209)
Rett syndrome (24)
RNA editing (6)
RSV (55)
Schizophrenia (94)
Series A (130)
Series B (108)
Service/supplier (3)
Sickle cell disease (55)
Special edition (12)
Spinal muscular atrophy (89)
Sponsored (15)
Startups (1153)
State (1)
Stomach cancer (7)
Supply chain (57)
Tariffs (30)
The Weekly (23)
Vaccines (513)
Venture capital (49)
Weight loss (274)
Women's health (47)
Worklife (10)
Date
Today (179)
Last 7 days (459)
Last 30 days (1582)
Last 365 days (17946)
2026 (2713)
2025 (18208)
2024 (16899)
2023 (16187)
2022 (20646)
2021 (20272)
2020 (19028)
2019 (16794)
2018 (12749)
2017 (11970)
2016 (10566)
2015 (12717)
2014 (9228)
2013 (7262)
2012 (7941)
2011 (8061)
2010 (7267)
Location
Africa (321)
Alabama (29)
Alaska (2)
Arizona (92)
Arkansas (6)
Asia (16217)
Australia (2483)
California (6746)
Canada (1845)
China (662)
Colorado (266)
Connecticut (346)
Delaware (248)
Europe (36264)
Florida (832)
Georgia (178)
Hawaii (3)
Idaho (18)
Illinois (508)
India (33)
Indiana (292)
Iowa (11)
Japan (333)
Kansas (56)
Kentucky (15)
Louisiana (14)
Maine (48)
Maryland (699)
Massachusetts (4770)
Michigan (128)
Minnesota (294)
Mississippi (5)
Missouri (75)
Montana (8)
Nebraska (8)
Nevada (70)
New Hampshire (33)
New Jersey (1931)
New Mexico (9)
New York (1674)
North Carolina (720)
North Dakota (3)
Northern California (3334)
Ohio (152)
Oklahoma (6)
Oregon (13)
Pennsylvania (1156)
Puerto Rico (12)
Rhode Island (18)
South America (473)
South Carolina (18)
Southern California (2595)
Tennessee (85)
Texas (1055)
United States (22906)
Utah (147)
Virginia (158)
Washington D.C. (33)
Washington State (592)
West Virginia (3)
Wisconsin (101)
Wyoming (2)
251,639 Results for "5".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Da Vinci 5 Cleared for Cardiac Procedures
January 27, 2026
·
6 min read
Collaboration
Kite Makes $1.5B+ Cell Therapy Pact With Pregene as Others Pull Back
With more than $1.5 billion on the line, Gilead looks to bolster its CAR T portfolio.
October 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
BioRestorative Announces Closing of $5.0 Million Public Offering
February 15, 2026
·
5 min read
Press Releases
RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%
February 17, 2026
·
15 min read
Press Releases
BioRestorative Announces Pricing of $5.0 Million Public Offering
February 12, 2026
·
5 min read
Press Releases
Neurogene to Participate in Upcoming Investor Conferences - February 5, 2026
February 5, 2026
·
1 min read
Press Releases
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
February 8, 2026
·
3 min read
Press Releases
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
February 26, 2026
·
1 min read
Press Releases
Climb Bio to Present at Upcoming Investor Conferences - February 5, 2026
February 5, 2026
·
1 min read
Press Releases
1910 Publishes CANDID-CNS™, an AI Model That Unlocks Beyond Rule of 5 Chemical Space and Stereochemistry to Predict Blood–Brain Barrier Penetration
● CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. ● CANDID-CNS™ distinguishes CNS penetrant stereoisomers at 68% compared to 50% by Pfizer’s CNS MPO. ● Published in the Journal of Chemical Information and Modeling, CANDID-CNS™ presents a breakthrough in AI Drug Discovery by unlocking the potential of bRo5 and stereochemistry to significantly expand the chemical space of small molecules that can be developed into CNS therapeutics.
December 4, 2025
·
1 min read
1 of 25,164
Next
